# US 2023/0398135 A1 · Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398135 A1
- Document ID: US20230398135A1
- Status: Published application
- Kind: A1
- Application number: 18/304,373
- Filed: 2023-04-21
- Published: 2023-12-14
- Earliest claimed: 2022-06-08
- Assignees: Angrow Company Limited
- Applicants: Angrow Company Limited
- Inventors: Dengfeng YANG; Chunfeng CHAI; Xuan TAN
- Web page: https://patentgrep.com/patent/US20230398135A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/10: Anti-acne agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions including cannabinoid and use thereof are provided in the present disclosure. In some embodiments, the composition may include cannabidiol (CBD), cannabigerol (CBG), and bakuchiol (BAK). A molar concentration ratio of CBD, CBG, and BAK may be 1:1:1 in the composition. A molar concentration of CBD in the composition may be in a range of 1.67 μM to 16.7 μM.

## Claims

### Claim 1

A composition, comprising:
cannabidiol (CBD), cannabigerol (CBG), and bakuchiol (BAK), wherein a molar concentration ratio of CBD, CBG, and BAK is 1:1:1 in the composition, and a molar concentration of CBD in the composition is in a range of 1.67 μM to 16.7 μM.

### Claim 2 (depends on 1)

The composition of claim 1, wherein a total CBD/CBG/BAK molar concentration of the composition is in a range of 5 μM to 50 μM, the total CBD/CBG/BAK molar concentration of the composition being defined by a sum of molar concentrations of CBD, CBG, and BAK in the composition.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the total CBD/CBG/BAK molar concentration of the composition is 5 μM, 10 μM, 12.5 μM, 25 μM, or 50 μM.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the composition has an inhibitory activity against cyclooxygenase (COX)-2 in vitro.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the composition has a target total CBD/CBG/BAK molar concentration that exhibits a synergistic anti-inflammatory effect, a combination index of CBD, CBG, and BAK in the composition corresponding to the target-total CBD/CBG/BAK molar concentration being less than 1.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The composition of claim 5, wherein the target total CBD/CBG/BAK molar concentration of the composition is 10 μM.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition is configured to suppress activity of a pro-inflammatory cytokine.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition has an antioxidant activity.

### Claim 11 (depends on 1)

The composition of claim 1, further comprising an active component for treating acne or repairing acne scars.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the active component comprises at least one of a hydroxy acid, an additional cannabinoid, or a cannaflavin.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the additional cannabinoid comprises at least one of cannabidiolic acid (CBDA) or cannabigerolic acid (CBGA), or the cannaflavin comprises at least one of cannaflavin A or cannaflavin B.

### Claim at position 14

14-20. (canceled)

### Claim 21

A composition, comprising:
cannabidiol (CBD), cannabigerol (CBG), and bakuchiol (BAK), wherein
a molar concentration of CBD in the composition is in a range of 1.67 μM to 16.7 μM;
a total CBD/CBG/BAK molar concentration of the composition is in a range of 5 μM to 50 μM, the total CBD/CBG/BAK molar concentration of the composition being defined by a sum of molar concentrations of CBD, CBG, and BAK in the composition; and
the composition has a synergistic anti-inflammatory effect or an additive anti-inflammatory effect.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the synergistic anti-inflammatory effect or the additive anti-inflammatory effect is measured by inhibitory effect against COX-2 in vitro.

### Claim 23 (depends on 21)

The composition of claim 21, wherein the total CBD/CBG/BAK molar concentration of the composition is in a range of 9 μM to 11 μM.

### Claim 24 (depends on 21)

The composition of claim 21, further comprising cannabidiolic acid (CBDA) or cannabigerolic acid (CBGA).

### Claim 25 (depends on 21)

The composition of claim 21, wherein a molar concentration ratio of CBD, CBG, and BAK is 1:1:1.

### Claim 26

A composition, comprising:
cannabidiol (CBD), cannabigerol (CBG), and bakuchiol (BAK), wherein
a molar concentration ratio of CBD, CBG, and BAK is 1:1:1 in the composition;
a molar concentration of CBD in the composition is in a range of 1.67 μM to 16.7 μM;
the composition has a synergistic anti-inflammatory effect at a first total CBD/CBG/BAK molar concentration, a combination index of CBD, CBG, and BAK in the composition corresponding to the first total CBD/CBG/BAK molar concentration being less than 1; and
the composition has an additive anti-inflammatory effect at a second total CBD/CBG/BAK molar concentration, wherein:
the second total CBD/CBG/BAK molar concentration is greater than the first total CBD/CBG/BAK molar concentration.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the first total CBD/CBG/BAK molar concentration is in a range of 9 μM to 11 μM.

### Claim 28 (depends on 26)

The composition of claim 26, wherein the second total CBD/CBGBAK molar concentration is greater than 11 μM.

### Claim 29 (depends on 26)

The composition of claim 26, wherein the composition has a total CBD/CBG/BAK molar concentration of 10 μM.
